This page catalogs biotechnology and pharmaceutical companies developing AMPK (AMP-activated protein kinase) activator therapies for Parkinson's disease (PD). AMPK is a central regulator of cellular energy homeostasis and represents a promising therapeutic target for neurodegenerative diseases.
| Total Companies | 6 |
|---|---|
| Phase 2 | 1 |
| Phase 1 | 1 |
| Preclinical | 4 |
AMPK activation represents a promising therapeutic approach for Parkinson's disease because:
Companies listed below are developing direct AMPK activators or repurposing existing AMPK-activating drugs for PD.
Ticker: NASDAQ: NVO
Headquarters: Copenhagen, Denmark
Novo Nordisk is evaluating Metformin, a known AMPK activator, in Parkinson's disease clinical trials. Metformin activates AMPK through mitochondrial complex I inhibition and has established safety data from decades of diabetes use.
| Drug | Mechanism | Phase | Trial ID |
|---|---|---|---|
| Metformin | AMPK activator (Complex I inhibition) | Phase 2 | NCT04032361 |
| Metformin | AMPK activator (cognitive effects) | Phase 2 | NCT03790617 |
Metformin represents a repurposing opportunity with a well-established safety profile. The company leverages its metabolic disease expertise to explore neurodegenerative applications. [1]
Related pages:
Ticker: NYSE: LLY
Headquarters: Indianapolis, Indiana, USA
Eli Lilly has explored Metformin in Parkinson's disease trials and maintains a broad program in metabolic-neurodegeneration intersection. Their metabolic disease portfolio positions them well for AMPK-related approaches.
| Drug | Mechanism | Phase | Status |
|---|---|---|---|
| Metformin | AMPK activator | Phase 2 | Completed |
Related pages:
###Research Compounds with AMPK Activity
The following companies and research groups have developed novel AMPK activator compounds in preclinical stages:
| Company | Compound | Mechanism | Development Stage |
|---|---|---|---|
| Various (Academic) | AICAR | Direct AMPK activator (ZMP analog) | Research |
| Various (Academic) | PT1 | Allosteric AMPK activator | Research |
| Various (Academic) | A-769662 | Direct β1 subunit activator | Research |
| Various (Academic) | Thienopyridone derivatives | Brain-penetrant AMPK activators | Preclinical |
Note: AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a ZMP analog that directly activates AMPK. However, brain penetration has been limited. Current research focuses on:
Related pages:
Several companies have programs that activate AMPK through indirect mechanisms:
| Company | Drug/Approach | Indirect AMPK Activation | Status |
|---|---|---|---|
| Novo Nordisk | Semaglutide | GLP-1R agonism → AMPK activation | Phase 2 |
| Neuraly | NLY01 | GLP-1R agonism → AMPK activation | Phase 2 |
| Clene Nanomedicine | CNM-Au8 | Mitochondrial support → secondary AMPK effect | Phase 2 |
These companies target pathways that result in secondary AMPK activation, contributing to neuroprotection.
Related pages:
| Trial ID | Drug | Company | Phase | Status |
|---|---|---|---|---|
| NCT04032361 | Metformin | Novo Nordisk | Phase 2 | Completed |
| NCT03790617 | Metformin | Various | Phase 2 | Completed |
AMPK (AMP-activated protein kinase) is a central cellular energy sensor that:
In PD, dopaminergic neurons face chronic energy deficits, making AMPK activation a logical therapeutic approach.